Bajada S
Aust N Z J Med. 1979 Dec;9(6):709-12. doi: 10.1111/j.1445-5994.1979.tb04206.x.
The clinical response to therapy with dihydroergotamine (DHE) has been evaluated in one patient with idiopathic orthostatic hypotension. The results of tests performed on the autonomic nervous system are recorded, and the evidence for a central defect in postural blood pressure control is presented. Tilt table testing over a two-month period confirmed the beneficial effect of the medication in preventing profound falls of blood pressure. The dose required (20 mg/day) was higher than previously reported.
已对一名特发性直立性低血压患者使用双氢麦角胺（DHE）治疗的临床反应进行了评估。记录了对自主神经系统进行的测试结果，并给出了姿势性血压控制存在中枢缺陷的证据。为期两个月的倾斜台测试证实了该药物在预防血压大幅下降方面的有益效果。所需剂量（20毫克/天）高于先前报道的剂量。
